MarketCap
Facebook
X
TelegramFluidigm Corporation Revenue | FLDM
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Fluidigm Corporation
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 138 M | 117 M | 113 M | 102 M | 104 M | 115 M | 116 M | 71.2 M | 52.3 M | 42.9 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 138 M | 42.9 M | 97.2 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 235.0 | 0.36 % | $ 26.1 B |  USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
IDEXX Laboratories
IDXX
|
4.3 B | $ 560.36 | 2.41 % | $ 45.1 B | USA |
 |
Personalis
PSNL
|
69.6 M | $ 15.65 | 0.19 % | $ 1.4 B | USA |
 |
Quidel Corporation
QDEL
|
1.66 B | $ 12.91 | 0.29 % | $ 544 M | USA |
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
7.66 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | USA |
 |
Interpace Biosciences
IDXG
|
38.7 M | $ 6.47 | 2.11 % | $ 28.6 M | USA |
 |
Organovo Holdings
ONVO
|
131 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
30.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
2.86 B | - | -0.91 % | $ 14.7 B | USA |
 |
Soleno Therapeutics
SLNO
|
190 M | - | - | $ 2.69 B | USA |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Biomerica
BMRA
|
4.45 M | $ 1.85 | 3.0 % | $ 5.39 M | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 3.98 | 4.82 % | $ 369 M | USA |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 1.73 | 0.73 % | $ 519 M | USA |
 |
Neuronetics
STIM
|
149 M | $ 1.89 | 3.45 % | $ 125 M | USA |
 |
Agilent Technologies
A
|
6.95 B | $ 172.97 | 0.07 % | $ 49.1 B | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 300.15 | 0.79 % | $ 14.9 B | USA |
|
Biodesix
BDSX
|
88.5 M | $ 23.66 | 3.0 % | $ 179 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
540 M | $ 12.9 | 6.78 % | $ 136 M | China |
 |
Bioventus
BVS
|
568 M | $ 13.3 | 0.94 % | $ 886 M | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Co-Diagnostics
CODX
|
622 K | $ 0.65 | 11.61 % | $ 865 K | USA |
 |
Fulgent Genetics
FLGT
|
323 M | $ 19.81 | 1.57 % | $ 610 M | USA |
 |
Surmodics
SRDX
|
126 M | - | - | $ 608 M | USA |
 |
Illumina
ILMN
|
4.34 B | $ 262.54 | 0.3 % | $ 40.7 B | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
5.39 B | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
2.29 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 317.95 | 0.09 % | $ 26.5 B | USA |
 |
Psychemedics Corporation
PMD
|
19.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 99.7 | 0.03 % | $ 6.73 B | USA |
 |
T2 Biosystems
TTOO
|
7.19 M | - | -39.35 % | $ 313 K | USA |
 |
Meridian Bioscience
VIVO
|
333 M | - | - | $ 1.49 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
11.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Anixa Biosciences
ANIX
|
210 K | $ 2.67 | 4.71 % | $ 86.7 K | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 618.47 | 1.94 % | $ 17.8 B | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |